London, September 2025 — A groundbreaking study conducted in Europe has revealed alarming findings: beta blockers, a standard drug given after heart attacks, may significantly increase health risks for women if their heart pumping function remains normal.
What the Study Found
The research, published in the prestigious New England Journal of Medicine and the European Heart Journal, shows that women who suffer a mild heart attack — where the heart’s left ventricular ejection fraction (LVEF) remains preserved — face a much higher risk when prescribed beta blockers.
Key findings include:
- Women with preserved heart function given beta blockers were three times more likely to suffer a repeat heart attack, heart failure, or even death.
- In the study of 1,627 women, those taking beta blockers faced a 45% higher risk of cardiovascular death compared to those not on the medication.
- The broader clinical trial, called REBOOT, examined 8,500 patients across 109 hospitals in Spain and Italy, reinforcing that both men and women with normal heart function saw no measurable benefit from beta blocker therapy post-heart attack.
What Are Beta Blockers?
Beta blockers are a widely used class of drugs that act on the heart and blood vessels. They:
- Slow the heart rate
- Lower blood pressure
- Reduce strain on the heart
Traditionally, they have been considered life-saving for patients after a heart attack by reducing the risk of recurrent cardiac events. However, the new data challenges this long-standing medical practice, especially in women.
Why Women Are More at Risk
The study highlights a crucial gap in cardiovascular medicine: most historic trials on beta blockers were conducted primarily on men, with little gender-specific analysis. Women’s heart physiology, hormonal influences, and different risk profiles may explain why beta blockers could backfire in certain female patients.
Dr. Luis Rodríguez, a cardiologist involved in the study, explained:
“For decades, we prescribed beta blockers almost automatically after a heart attack. This research shows we must now differentiate. In women with preserved ejection fraction, these drugs can actually do more harm than good.”
Implications for Clinical Practice
The results are expected to reshape international cardiology guidelines, as many doctors still prescribe beta blockers universally after myocardial infarction (MI).
Implications include:
- Personalized treatment: Women may need different therapeutic approaches after heart attacks, with closer monitoring before prescribing beta blockers.
- Guideline revision: Health authorities in Europe and beyond may soon recommend restricting beta blocker use only to patients with reduced ejection fraction or other specific conditions.
- Risk-benefit reassessment: Doctors must weigh the potential risks for female patients rather than following a one-size-fits-all approach.
Global Health Perspective
Cardiovascular disease remains the leading cause of death in women worldwide, yet women are often underrepresented in clinical trials. This discovery adds urgency to calls for sex-specific research in cardiology.
Dr. Maria Hernández, a co-author, noted:
“We’ve learned that what works for men cannot always be assumed to work for women. Future studies must design therapies with gender differences in mind.”
What Patients Should Know
Experts emphasize that women who have suffered a heart attack should not stop taking prescribed medication on their own. Instead, they should:
- Discuss the findings with their doctor
- Request an assessment of their heart’s ejection fraction
- Explore alternative treatments if heart function is preserved
Conclusion
This study represents a turning point in cardiac medicine. While beta blockers remain valuable for many heart patients, their blanket use after heart attacks is now under scrutiny. For women, particularly those whose hearts are still functioning strongly, the drug may do more harm than good.
